

toxicology, pharmacology, addiction, or any other relevant specialty.

In addition to the voting members, the committee shall include three nonvoting members who are identified with industry interests. These members shall include one representative of the tobacco manufacturing industry, one representative of the interests of tobacco growers, and one representative of the interests of the small business tobacco manufacturing industry.

### III. Nomination Procedures

Any interested person may nominate one or more qualified individuals for membership on the advisory committee. Self-nominations are also accepted. Nominations must include a current, complete résumé or curriculum vitae for each nominee, including current business address and/or home address, telephone number, and email address if available. Nominations must also specify the advisory committee for which the nominee is recommended. Nominations must also acknowledge that the nominee is aware of the nomination unless self-nominated. FDA will ask potential candidates to provide detailed information concerning such matters related to financial holdings, employment, and research grants and/or contracts to permit evaluation of possible sources of conflicts of interest.

This notice is issued under the Federal Advisory Committee Act (5 U.S.C. app. 2) and 21 CFR part 14, relating to advisory committees.

Dated: October 21, 2013.

**Jill Hartzler Warner,**

*Acting Associate Commissioner for Special Medical Programs.*

[FR Doc. 2013-25541 Filed 10-28-13; 8:45 am]

**BILLING CODE 4160-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Center for Scientific Review; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the Transplantation, Tolerance, and Tumor Immunology Study Section, October 3, 2013, 8:30 a.m. to October 4, 2013, 12:00 p.m., Renaissance Washington DC, Dupont Circle, 1143 New Hampshire Avenue NW., Washington, DC 20037 which was published in the **Federal Register** on September 9, 2013, 78 FR 174 pgs. 55086-55087.

The meeting will be held at the Washington Plaza Hotel, 10 Thomas Circle NW., Washington, DC 20005. The

meeting will start on November 21, 2013 at 8:00 a.m. and will end on November 22, 2013 at 1:00 p.m. The meeting is closed to the public.

Dated: October 24, 2013.

**Carolyn A. Baum,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2013-25553 Filed 10-28-13; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Biomedical Imaging and Bioengineering; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the National Institute of Biomedical Imaging and Bioengineering Special Emphasis Panel, October 11, 2013, 10:00 a.m. to 5:00 p.m., National Institutes of Health, Two Democracy Plaza, Suite 959, 6707 Democracy Boulevard, Bethesda, MD 20892, which was published in the **Federal Register** on July 26, 2013, 78 FR 45254.

The meeting notice is amended to change the date from October 22, 2013, to November 19-20, 2013 at 8:00 a.m. to 6:00 p.m. The location remains the same. The meeting is closed to the public.

Dated: October 23, 2013.

**David Clary,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2013-25470 Filed 10-28-13; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Biomedical Imaging and Bioengineering; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the National Institute of Biomedical Imaging and Bioengineering Special Emphasis Panel, October 22, 2013, 11:00 a.m. to 5:00 p.m., National Institutes of Health, Two Democracy Plaza, Suite 951, 6707 Democracy Boulevard, Bethesda, MD 20892, which was published in the **Federal Register** on September 10, 2013, 78 FR 55268.

The meeting notice is amended to change the date from October 22, 2013, to December 11, 2013. The time and location remains the same. The meeting is closed to the public.

Dated: October 23, 2013.

**David Clary,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2013-25468 Filed 10-28-13; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Center for Scientific Review; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the Tumor Cell Biology Study Section, October 16, 2013, 08:00 a.m. to October 17, 2013, 05:00 p.m., Hotel Kabuki, 1625 Post Street, San Francisco, CA 94115 which was published in the **Federal Register** on September 17, 2013, 78 FR 57169.

The meeting will be held at the National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892. The meeting will start on November 16, 2013 at 8:00 a.m. and end on November 17, 2013 at 7:00 p.m. The meeting is closed to the public.

Dated: October 23, 2013.

**David Clary,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2013-25494 Filed 10-28-13; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Center for Scientific Review; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the Center for Scientific Review Special Emphasis Panel, October 11, 2013, 08:00 a.m. to October 11, 2013, 05:00 p.m., Doubletree Hotel Washington, 1515 Rhode Island Ave. NW., Washington, DC 20005 which was published in the **Federal Register** on September 11, 2013, 78 FR Pgs. 55752-55753.

The meeting will be held at National Institutes of Health, 6701 Rockledge Dr., Bethesda, MD 20892. The meeting will start on November 15, 2013 at 9:00 a.m. and end on November 15, 2013 at 4:00 p.m. The meeting is closed to the public.